Patients do not always respond equally to a specific treatment, but when research can predict the efficacy or ineffectiveness of a treatment on a case-by-case basis, this implies a real improvement in the therapeutic care.

As far as Inflammatory Bowel Diseases (IBD) are concerned for example, 40% of patients, ie.  2 million people worldwide, do not respond to anti-TNF, an immunosuppressive treatment to prevent relapses of the disease.

A recent study conducted by researchers of the Kennedy Institute (University of Oxford) and published in “Nature Medicine” may identify IBD patients non- responding to anti -TNF treatment. Indeed, the researchers observed a lesser response by subjects with a high concentration of a cytokine, oncostatin M (OSM). Following this discovery, researchers are searching different ways to block this cytokine, allowing non-responding patients to become receptive to anti -TNF. 1

“Such an approach paves the way to a personalized treatment of the disease. It may allow to avoid exposure of non-responding patients to this treatment, which has non negligible side effects, and also interestingly to optimize healthcare costs for this expensive treatment.
Concerning the anti -TNF treatment as such, let us remember the importance for the patients of a good intestinal flora in order to better face these treatments.”

Pr De Simone, About

Share this article!

Categories: DSF, IBD

Keep connected, Subscribe

Probiotixx

The Letter of Probiotics

Probiotixx

The Letter of Probiotics

No spamming, no advertising. Science.

Subscribe to Pr De Simone’s blog. Get his latest analysis on the ever-evolving field of probiotics and their involvement in cutting-edge therapies.